Citadel Advisors
CNCR

Citadel Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Citadel Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,735
Closed -$411K – 14372
2024
Q1 		$411K Buy
+24,735
New +$381K ﹤0.01% 8814
2023
Q2 		– Sell
-26,011
Closed -$312K – 14437
2023
Q1 		$312K Buy
26,011
+12,390
+91% +$169K ﹤0.01% 9305
2022
Q4 		$187K Sell
13,621
-7,200
-35% -$105K ﹤0.01% 10245
2022
Q3 		$305K Buy
+20,821
New +$336K ﹤0.01% 9544
2022
Q2 		– Sell
-14,275
Closed -$257K – 12990
2022
Q1 		$257K Buy
+14,275
New +$271K ﹤0.01% 10936
2021
Q3 		– Sell
-46,951
Closed -$1.5M – 13869
2021
Q2 		$1.5M Buy
46,951
+4,123
+10% +$124K ﹤0.01% 7322
2021
Q1 		$1.27M Buy
42,828
+33,674
+368% +$1.1M ﹤0.01% 7494
2020
Q4 		$290K Sell
9,154
-15,491
-63% -$465K ﹤0.01% 9138
2020
Q3 		$675K Buy
24,645
+3,099
+14% +$82.9K ﹤0.01% 6754
2020
Q2 		$588K Sell
21,546
-1,132
-5% -$27.8K ﹤0.01% 6782
2020
Q1 		$450K Sell
22,678
-12,221
-35% -$263K ﹤0.01% 6630
2019
Q4 		$818K Sell
34,899
-5,084
-13% -$108K ﹤0.01% 5960
2019
Q3 		$743K Buy
39,983
+3,408
+9% +$69.2K ﹤0.01% 6097
2019
Q2 		$771K Buy
36,575
+2,711
+8% +$55.8K ﹤0.01% 6124
2019
Q1 		$712K Buy
+33,864
New +$711K ﹤0.01% 6187
2017
Q1 		– Sell
-12,144
Closed -$257K – 7484
2016
Q4 		$257K Buy
+12,144
New +$279K ﹤0.01% 5896
2016
Q2 		– Sell
-10,126
Closed -$220K – 6868
2016
Q1 		$220K Buy
+10,126
New +$216K ﹤0.01% 5518

Other funds holding CNCR

Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return
RIA
Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SWA
SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's CNCR Position: Q2 2024 in Review

Citadel Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2024, closing a stake of 24,735 shares — an estimated $411K sold.

Citadel Advisors first reported a position in CNCR in Q1 2016 and held it in 17 quarters. The position peaked at $1.5M in Q2 2021. 13 funds tracked by Wall St. Rank hold CNCR as of Q2 2024.

  • Citadel Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 24,735 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2024, an estimated $411K.
  • Citadel Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2016 and held it in 17 quarters.
  • Citadel Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1.5M in Q2 2021.
  • 13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.